TRKA (G595R/A608D)
Sign in to save this workspaceNTRK1 · Variant type: compound · HGVS: p.G595R;p.A608D
Components
p.G595Rp.A608D
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 98.7% | 1.3% | 84.21 |
| 2 | Ponatinib | 95.3% | 4.7% | 78.23 |
| 3 | Entrectinib | 93.6% | 6.4% | 93.69 |
| 4 | Ripretinib | 81.8% | 18.3% | 92.95 |
| 5 | Cabozantinib | 76.5% | 23.5% | 92.73 |
| 6 | Darovasertib | 66.8% | 33.2% | 96.99 |
| 7 | Tivozanib | 43.7% | 56.3% | 92.42 |
| 8 | Pralsetinib | 38.0% | 62.0% | 93.43 |
| 9 | Defactinib | 30.8% | 69.2% | 92.68 |
| 10 | Alpelisib | 18.0% | 82.0% | 97.22 |
| 11 | Apatinib | 15.0% | 85.0% | 97.73 |
| 12 | Pexidartinib | 13.3% | 86.7% | 99.49 |
| 13 | Crizotinib | 12.7% | 87.3% | 91.39 |
| 14 | Abrocitinib | 12.1% | 87.9% | 99.50 |
| 15 | Upadacitinib | 11.7% | 88.3% | 97.98 |
| 16 | Bosutinib | 10.2% | 89.8% | 87.22 |
| 17 | Mitapivat | 9.4% | 90.6% | 100.00 |
| 18 | Tenalisib | 9.4% | 90.6% | 97.98 |
| 19 | Tucatinib | 9.3% | 90.7% | 99.75 |
| 20 | Umbralisib | 9.0% | 91.0% | 98.74 |
| 21 | Nintedanib | 8.8% | 91.3% | 90.23 |
| 22 | Tepotinib | 8.5% | 91.5% | 99.75 |
| 23 | Afatinib | 7.9% | 92.1% | 98.50 |
| 24 | Fedratinib | 7.8% | 92.2% | 96.21 |
| 25 | Ruxolitinib | 7.5% | 92.5% | 98.25 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 98.7% | 98.9% | -0.2% |
| Ponatinib | 95.3% | 98.4% | -3.0% |
| Entrectinib | 93.6% | 99.0% | -5.4% |
| Ripretinib | 81.8% | 93.6% | -11.8% |
| Cabozantinib | 76.5% | 93.6% | -17.1% |
| Darovasertib | 66.8% | — | — |
| Tivozanib | 43.7% | 85.7% | -42.0% |
| Pralsetinib | 38.0% | 98.7% | -60.6% |
| Defactinib | 30.8% | 80.3% | -49.5% |
| Alpelisib | 18.0% | 97.5% | -79.5% |
| Apatinib | 15.0% | — | — |
| Pexidartinib | 13.3% | — | — |
| Crizotinib | 12.7% | 95.8% | -83.1% |
| Abrocitinib | 12.1% | — | — |
| Upadacitinib | 11.7% | — | — |
| Bosutinib | 10.2% | 67.0% | -56.8% |
| Mitapivat | 9.4% | — | — |
| Tenalisib | 9.4% | 59.0% | -49.7% |
| Tucatinib | 9.3% | — | — |
| Umbralisib | 9.0% | — | — |
| Nintedanib | 8.8% | 93.8% | -85.0% |
| Tepotinib | 8.5% | — | — |
| Afatinib | 7.9% | — | — |
| Fedratinib | 7.8% | 56.2% | -48.4% |
| Ruxolitinib | 7.5% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 31.2ms